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ABSTRACT      
 
The prevalence of obesity and type 2 diabetes (T2DM) is increasing worldwide, making it 
one of the biggest health problems currently facing both developed and developing 
countries. The interactions between environmental signals and genes in the development of 
obesity and T2DM are poorly understood. 
Alternative splicing can result in the generation of more than one protein from a single 
gene or in the complete switch off of the protein. Many different human diseases can be 
caused by impairment of alternative splicing or its regulation, resulting from genetic 
variations and environmental signals.  
The main aim of the present study was to investigate interactions between alternative 
splicing of the genes and obesity. We aimed to investigate whether the expression profile of 
splice variants in human adipose tissue differs depending on fat depots and whether the 
splicing pattern significantly changes in response to weight loss. 
The first study focused on the regulation of alternative splicing of candidate gene, 
TCF7L2, in obesity and weight loss. The distribution of TCF7L2 splice variants was 
determined in subcutaneous and visceral adipose tissue and the livers of obese individuals. 
Furthermore, we demonstrated that weight loss regulates alternative splicing of TCF7L2 in 
both subcutaneous adipose tissue and liver. We found that adipose tissue TCF7L2 splicing 
was strongly associated with FFAs levels, suggesting an effect on insulin action in adipose 
tissue. 
The second study investigated the relationship between splicing of insulin receptor gene 
(ISNR) and obesity or T2DM. Our results showed regulation of INSR splicing by weight 
loss in subcutaneous fat. Additionally, we found a strong correlation between splice 
variants and insulin levels in both fat depots.  
In the third study we identified alternatively spliced genes in 11 obesity loci. We 
demonstrated that weight loss induced regulation of MSH5 gene and that splicing of BAT6 
and TRA2B is fat depot dependent. Statistical analyses revealed that BMI is a main 
determinant of TRA2B, BAG6 and MSH5 splicing in subcutaneous fat. 
The forth publication included in this thesis is a review of literature with respect to the 
role of alternative splicing in obesity and weight loss.  
This thesis provides new information on the role of alternative splicing in pathogenesis 
of obesity and T2DM. These findings increase our understanding of splicing dysregulations 
and can improve the chances for a more targeted treatment and more accurate diagnostics. 
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TIIVISTELMÄ 
 
Lihavuuden ja tyypin 2 diabeteksen yleisyys lisääntyy maailmanlaajuisesti tehden niistä 
suurimman kansanterveysongelman, joka koskettaa sekä teollisuus- että kehitysmaita. 
Tyypin 2 diabetes ja lihavuus voivat molemmat kehittyä itsenäisesti johtuen geneettisten ja 
ympäristötekijöiden vaikutuksesta, mutta tästä yhteydestä on vain vähän tietoa.   
Yhden geenin vaihtoehtoinen silmukointi voi johtaa useamman kuin yhden proteiinin 
muodostumiseen tai täydelliseen proteiinin toiminnan loppumiseen. Geenin 
silmukointiprofiili saattaa muuttua tapauksesta ja ympäristöstä riippuen. Ihmisillä monet 
sairaudet saattavat johtua vaihtoehtoisen silmukoinnin viasta tai sen säätelystä, 
geneettisistä variaatioista ja ympäristötekijöistä johtuen.   
Tämän väitöskirjatyön kokonaistavoite oli tutkia geenien vaihtoehtoisen silmukoinnin ja 
lihavuuden vuorovaikutusta. Tavoitteenamme oli selvittää muuttuuko 
transkriptivarianttien ilmentymisprofiili ihmisen rasvakudoksessa riippuen rasvan 
sijaintikohdasta ja muuttuuko silmukointimalli laihdutuksen vaikutuksesta.  
Ensimmäisessä osajulkaisussa keskityttiin kandidaattigeenin, TCF7L2, vaihtoehtoisen 
silmukoinnin säätelyyn lihavuudessa ja laihdutuksessa. TCF7L2-transkriptivarianttien 
jakautuminen määritettiin lihavien yksilöiden ihonalaisesta ja viskeraalisesta 
rasvakudoksesta ja maksasta. Tutkimuksessa osoitimme, että laihtuminen säätelee 
TCF7L2:n vaihtoehtoista silmukointia ihonalaisessa rasvakudoksessa ja maksassa. 
Totesimme, että rasvakudoksen TCF7L2:n silmukointi oli vahvasti yhteydessä vapaiden 
rasvahappojen pitoisuuksiin vihjaten vaikutuksesta insuliinin toimintaan rasvakudoksessa. 
Toisessa osajulkaisussa tutkittiin insuliinireseptorigeenin, ISNR, vaihtoehtoisen 
silmukoinnin, lihavuuden ja tyypin 2 diabeteksen välistä yhteyttä. Tuloksemme osoittivat 
kuitenkin laihdutuksen säätelevän ISNR-geenin silmukointia ihonalaisessa 
rasvakudoksessa. Lisäksi havaitsimme vahvan korrelaation sekä ihonalaisen että 
viskeraalisen transkriptivarianttien ja insuliinipitoisuuksien välillä.  
Kolmannessa osajulkaisussa tunnistimme vaihtoehtoisesti silmukoituja geenejä 11:ssä 
lihavuuslokuksessa. Osoitimme laihdutuksen säätelevän MSH5-geenin ilmentymistä ja 
BAT6- ja TRA2B-geenien vaihtoehtoisen silmukoinnin riippuvan rasvan sijaintikohdasta. 
Tilastolliset analyysit osoittivat, että painoindeksi on ihonalaisen rasvakudoksen TRA2B:n, 
BAG6:n ja MSH5:n silmukoinnin määräävä tekijä. 
Väitöskirjatyöhön kuuluva neljäs osajulkaisu on kirjallisuuskatsaus vaihtoehtoisen 
silmukoinnin roolista lihavuudessa ja laihdutuksessa.  
Tämä väitöskirjatyö tarjoaa uutta tietoa vaihtoehtoisen silmukoinnin roolista lihavuuden 
ja tyypin 2 diabeteksen patogeneesissa. Nämä tulokset lisäävät ymmärrystämme 
vaihtoehtoisen silmukoinnin säätelyn häiriöissä ja voivat edistää kohdennettujen hoitojen 
mahdollisuuksia ja tarkempaa sairauksien diagnosointia. 
 
Luokitus: QT 235, QU 58.7, QU 475, WD 210 
Yleinen Suomalainen asiasanasto: geenit; geeniekspressio; lihavuus; ylipaino; rasvakudokset; maksa; insuliini; 
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 1 Introduction  
The prevalence of obesity is increasing worldwide, making it one of the biggest health 
problems currently facing both developed and developing countries. It has been long 
known that obesity is highly associated with insulin resistance and risk of type 2 diabetes 
(T2DM). However, obesity is not a homogeneous disorder and obese individuals differ in 
their body fat distribution.  Individuals with excess visceral fat tend to be at an increased 
risk of developing T2DM (1).  
The goal of obesity treatment is for an individual to reach and stay at a healthy weight. 
Because conventional treatments often fail to induce stable weight loss, bariatric surgery is 
currently the most effective approach that provides significant, sustained weight loss for 
patients who are severely obese (BMI> 40kg/m2)(2). Surprisingly, bariatric surgery turned 
out to be the most effective therapy for T2DM (3). One of the most commonly performed 
obesity surgeries is Roux-en-Y gastric bypass, which involves creating a small stomach 
pouch and attaching it directly to the small intestine, bypassing a large part of the stomach 
and duodenum. Interestingly, visceral adipose tissue is more sensitive to weight reduction 
than subcutaneous tissue, which is a consequence of higher metabolic and lipolytic activity 
in the visceral region than in other fat depots (4). Moreover it was shown that all forms of 
weight loss affect visceral fat more than subcutaneous fat (percentage wise) (5). 
Both T2DM and obesity are multifactorial complex diseases that are caused by a 
combination of genetic, environmental, and lifestyle factors. Obesity is a main risk factor for 
T2DM; however, these two conditions can also develop independently. The precise 
mechanisms linking the two conditions remain unclear as the interactions between 
environmental signals and genes in the development of obesity and T2DM are poorly 
understood.  
Linkage and candidate-gene focused studies allowed for the identification of genes 
causing monogenic forms of T2DM (6) and obesity (7). However, these approaches were 
largely unsuccessful when applied to the common forms of the diseases (8, 9). Both obesity 
and T2DM are complex diseases, which do not show Mendelian inheritance pattern, and 
are associated with multiple genetic and environmental factors. Recent advances using 
genome wide association analyses have substantially increased the number of confirmed 
candidate genes for obesity and T2DM. However, the functional polymorphisms in these 
loci have not been identified. Many of the discovered polymorphisms are localized in non-
coding sequences. Interestingly, at least 15% of all point mutations responsible for genetic 
diseases have been estimated to affect splicing (9, 10). The underlying mechanisms by 
which obesity and T2DM may or may not manifest together remain poorly understood. 
One possible explanation is that regulation of alternative splicing contributes to increased 
risk of obesity and T2DM.  
Alternative splicing can result in the production of multiple mRNA products, and thus 
allows the creation of more than one protein from a single gene or the switching off the 
protein by including a stop codon in its mRNA. According to recent reports, almost all 
human multi-exon genes undergo alternative splicing, which would compensate for the 
relatively low number of genes present in human genome (10, 11). Depending on the 
situation and environment, one gene can be transcribed into suitable transcript (12). While 
the abundance of transcripts is mainly influenced by the promoter activity, the alternative 
splicing reflects in the structure of transcripts and their encoded proteins, subsequently 
influencing protein localization, activity, binding properties and post-translational 
modifications of numerous proteins (13).  
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Many human diseases result from defective splicing of crucial transcripts or abnormal 
splice variants in affected tissues (14). There are numerous, well-characterized genes in 
which disruption of alternative splicing is a cause of disease. Additionally, some genes 
associated with obesity and insulin resistance have been shown to be regulated by 
alternative splicing (15-19). Interestingly, rare SNPs in obese subjects have been shown to 
be enriched in splicing regulatory regions of introns (20) suggesting that genetic regulation 
of splicing may contribute to obesity. Taken into account the widespread occurrence of 
alternative splicing and its highly complex regulation, it is not surprising that dysregulation 
of normal splicing patterns can cause or modify human disease (21).  A better 
understanding of these dysregulations can improve the chances for a more targeted 
treatment and more accurate diagnostics.  
The key finding leading to studies described in this thesis was the report by Pihlajamäki 
et al. demonstrating that expression of several genes involved in RNA processing is 
decreased in both liver and skeletal muscle of obese humans (22), indicating that aberrant 
splicing in obesity might be a general phenomenon. The main aim of the present study was 
to determine the effect of obesity and weight loss on alternative splicing of candidate genes 
(TCF7L2 and INSR) as well as to identify alternatively spliced genes in obesity loci in 
Kuopio Obesity Surgery (KOBS), very low calorie diet (VLCD), Metabolic Syndrome in 
Men (METSIM) and European Network on Functional Genomics of Type 2 Diabetes 
(EUGENE2) studies. We aimed to investigate whether the expression profile of splice 
variants in human adipocytes differs depending on fat depots and whether the splicing 
pattern significantly changes in response to weight loss. 
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2 Review of the Literature 
2.1 OBESITY 
2.1.1 Pathophysiology of obesity 
Overweight and obesity are defined as abnormal or excessive fat accumulation that 
presents a risk to health (World Health Organization definition). Body mass index (BMI) 
has been used as a marker for overweight and obesity. BMI is calculated as person’s weight 
(in kilograms) divided by the square of their height (in metres). An individual with a BMI 
equal to or more than 25 is considered overweight, a BMI of 30 or more indicates obesity, 
and BMI higher than 40 is considered severe obesity. Both overweight and obesity are well-
recognized risk factors for a number of chronic diseases, including diabetes, cardiovascular 
diseases and cancer (23, 24). A major consequence of obesity is development of T2DM, 
characterized by insulin resistance and impaired insulin secretion (25). Obesity contributes 
to the development of insulin resistance via the release of free fatty acids, increased 
inflammation, cytokine production, adipokine changes and fat accumulation in the liver 
and muscle (26). 
2.1.2 Adipose tissue 
Adipose tissue is the largest energy reservoir in the body. Adipose tissue provides 
insulation and mechanical support, but the primary function of adipocytes is to store 
triglycerides in lipid droplets and release free fatty acids (FFAs). In periods of energy 
excess, energy is deposited efficiently in adipose tissue in the form of triglycerides 
(lipogenesis), whereas in the fasting state lipid reserves are released (lipolysis). The number 
of adipocytes is set in childhood and adolescence and stays relatively constant throughout 
the life (27). However, it was demonstrated that around 10% of adipose cells undergo 
annual replacement (27) and that subjects with hypertrophy generated 70% less adipocytes 
per year than individuals with hyperplasia (28). Hypertrophic obesity is associated with an 
inability to differentiate new adipose cells due to an inability to inhibit Wnt/β-catenin 
signalling (29). In obesity, adipose tissue is overloaded with triglycerides, resulting in 
decreased buffering capacity for lipid storage in adipocytes and exposure of other tissues to 
excessive influx of FFAs (30). Triglyceride accumulation in non-adipose tissues (e.g. skeletal 
muscle, pancreatic islets and the liver) may play a role in the development of insulin 
resistance and/or impaired insulin secretion in obese individuals (31). Importantly, adipose 
tissue serves as an endocrine organ that secretes hormones and adipokines which are 
involved in glucose and lipid metabolism and inflammation (32). 
In addition to adipocytes, adipose tissue contains the stromal vascular fraction of 
adipose tissue, which includes preadipocytes, fibroblasts, vascular endothelial cells and a 
variety of immune cells.  
Adipogenesis is the process by which precursor cells differentiate to adipocytes. 
Inhibition of Wnt signalling has been demonstrated to be essential for adipogenesis to 
proceed (33, 34). Activation of canonical Wnt signalling pathway leads to inhibition of 
GSK3β resulting in stabilization of β-catenin in the cytoplasm. Translocation of β-catenin to 
the nucleus and its further binding to TCF/LEF transcription factors, including TCF7L2, 
activates downstream targets and inhibits adipogenesis (35). Insulin signalling cascade is 
also crucial in adipogenesis. Insulin induced activation of AKT inhibits GSK3β (36), 
whereas insulin mediated activation of ERK1/2 pathway activation promotes adipogenesis 
(37) (Figure 1). 
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Figure 1. Wnt/β-catenin and insulin signalling pathways in adipocyte metabolism.  
2.1.2.1 Subcutaneous and visceral fat depots 
Body fat distribution varies between individuals. Adipose tissue localized around 
abdominal cavity, stored around internal organs such as the liver, pancreas and intestines, 
known as visceral fat, differs from adipose tissue localized under the skin (subcutaneous 
fat). Accumulation of visceral fat has been associated with hyperglycemia, 
hyperinsulinemia, hypertriglyceridemia, impaired glucose tolerance, and increased 
apolipoprotein B-rich lipoproteins, all of which characterize the insulin resistance 
syndrome (1). The risk of insulin resistance, the metabolic syndrome and cardiovascular 
diseases are more strongly associated with increased visceral fat than BMI alone (38). 
Individuals with excess visceral fat tend to be at an increased risk of developing diabetes 
(1). Furthermore, visceral adipose tissue is more sensitive to weight reduction than 
subcutaneous tissue, which is a consequence of higher metabolic and lipolytic activity in 
the visceral region than in other fat depots (4). Additionally, several studies reported 
elevated inflammation in visceral than subcutaneous fat (39, 40), which may result from 
higher expression of proinflammatory genes in visceral fat (41). Moreover, there are gender 
differences in adipose fat distribution. In general, women store more fat in the 
subcutaneous, whereas men store more fat in the visceral adipose tissue (42). Molecular 
differences between visceral and subcutaneous adipose tissue are not fully known. We 
investigated the differences in exon splicing profiles (explained in the paragraph 2.4) of 
candidate genes between visceral and subcutaneous fat. 
2.1.3 Factors predisposing to obesity 
The fundamental cause of obesity is an imbalance between energy intake and energy 
expenditure, which leads to increased storage of fatty acids in expanded adipose tissue.  
Like many other diseases, obesity is a consequence of a complex interaction between an 
individual’s genetic make-up and the environmental factors that an individual is exposed 
to. The study on all together 929 monozygotic twins, dizygotic twins and so called virtual 
twins (non-biological siblings of the same age who are raised together since infancy), 
revealed that 63.6% of the total variance of BMI was explained by a non-additive genetic 
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component, 25.7% by a common environmental component, and the remaining 10.7% by an 
unshared component (43) indicating that both genetics and environmental factors affect 
BMI. 
2.1.3.1 Environmental factors 
Longitudinal and cross sectional studies have indicated clear associations between 
environment and obesity risk. Obesity is caused by the  changes in lifestyle over the past 
years, such as increase in the availability of energy-dense food, sedentary lifestyle and 
reduced physical activity, which create so called “obesogenic” environment 
(44). Additionally, environmental factors such as depression, sleep disorders and low 
socioeconomic status have been linked to obesity (45). The rapidity by which prevalence of 
obesity is increasing suggests that environmental factors, rather than slow changes in the 
human genome which occur in response to strong evolutionary pressures, have influenced 
the obesity epidemic.  
2.1.3.2 Genetics of obesity 
A significant body of evidence indicates that genetic factors play an important role in 
determining body weight (46). A study of twins separated from each other at birth and 
reared apart showed that twins were equally likely to be obese despite of the environment, 
such as what the parents and children ate, or how much they exercised (the intra-pair BMI 
correlation coefficients were 0.70 for men and 0.66 for women) (47). These and other results 
from twin studies suggest that genetic factors explain 50% to 90% of the variance in BMI 
(48). Genome wide association studies (GWAS) helped link genes to obesity risk. It was first 
expected that heritability of obesity would be explained by common genetic variations but 
each variant on its own has a very subtle effect on BMI. Recent GWAS analyses have 
identified 39 BMI associated loci (45), and each single variant raises body weight by 
approximately 180–1400 g (49). All the variants identified through GWAS explain only 
about 2–4% of the obesity risk (50). FTO (fat mass and obesity associated) gene was the first 
GWAS identified obesity locus, and it remains the one with the strongest effect, increasing 
BMI with a median per-allele change of 0.36 kg/m2 (51). There are a small number of known 
monogenic forms of obesity, accounting only for less than 1% of the cases (52). The most 
common form of obesity is polygenic, which means that it results from interaction of 
several genes, each of which may have relatively small effects (53). Despite the large 
number of common risk variants identified for many complex diseases (such as obesity or 
T2DM), the proportion of heritability they explain remains small, leading to the important 
question where the “missing heritability” might be found (54). There are several possible 
sources of explanation. First, there are other forms of DNA variation (including copy 
number variants, insertions, deletions, inversions and translocations) which cannot be 
detected with commercial SNP genotyping arrays (55). Additionally, as demonstrated on 
mice model, complex phenotypes (such as T2DM and obesity) have a very complex genetic 
architecture due to the joint action of many loci of small effects contributing to the total 
variance (56).  Another considered option to be a source of missing heritability is gene-gene 
interaction (G×G)(57, 58) as well as the gene-environment interaction (G×E) (54). Finally, 
epigenetic events, such as histone modifications, DNA methylation, and inherited 
expression of non-coding RNAs leave the genome intact, but modify the gene expression 
(59) and RNA splicing (60-63). Interestingly, it has been shown that some susceptibility 
variants for T2DM exhibit parental-origin specific associations. Moreover, rs2334499 was 
demonstrated to associate with T2DM when the risk allele was paternally inherited and 
was protective when maternally transmitted (64). Thus, to fully understand mechanisms 
behind the genetic predisposition, we need to relate them to the regulation of protein 
expression, which includes DNA sequence variations, joint action of several loci, chromatin 
remodelling, microRNAs and alternative splicing. Susceptibility to obesity is determined, to 
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a significant extent, by genetic predisposition, but an  “obesogenic” environment is 
necessary for obesity to occur (65). 
2.2 TYPE 2 DIABETES 
2.2.1 Pathophysiology of type 2 diabetes 
The main pathophysiological features of T2DM are impaired insulin secretion and 
increased insulin resistance which jointly contribute to the development of this disease. 
T2DM is a progressive disease which is characterized by decrease of functional pancreatic 
β-cell mass over time. T2DM is diagnosed based on elevated glucose levels or elevated 
hemoglobin A1c (HbA1c) levels. According to the American Diabetes Association (ADA) 
criteria, the diagnosis of T2DM is based on elevated HbA1c levels (≥6.5%) or fasting plasma 
glucose (FPG) levels (≥ 7.0 mmol/L) or elevated 2-hour plasma glucose (≥11.1 mmol/L) 
during an oral glucose tolerance test (OGTT) or, in patients with classic symptoms of 
hyperglycemia or hyperglycemic crisis, an elevated levels of random plasma glucose (≥11.1 
mmol/L) (66). 
2.2.1.1 Insulin secretion 
Insulin is exclusively produced by pancreatic β-cells of the islets of Langerhans and lowers 
plasma glucose concentration. (67). The release of insulin from β-cells, in response to 
changes in blood glucose concentrations following food ingestion, is a highly dynamic 
process. The process is initiated by the transport of glucose into the β-cells by GLUT1 and 
GLUT3 transporters (67). In the β-cells glucose is metabolized in a process initiated by 
glucose phosphorylation by the glucokinase (GK). The increased ATP/ADP ratio leads to 
closure of ATP-sensitive K+ channels (KATP) and depolarization of the membrane. 
Subsequently, activation of Ca2+ channels leads to increase of intracellular Ca2+ resulting in 
insulin release (68). Insulin release exhibits biphasic pattern. First phase is rapid and short 
lasting, followed by a second phase during which insulin release continues as long as the 
glucose concentration is elevated (69). In T2DM patients the first phase is absent and second 
phase is also lower than in normoglycemic subjects (70). Many of the T2DM associated risk 
variants identified to date regulate insulin secretion and not insulin action in insulin-
sensitive tissues (71). 
In healthy subjects, a postprandial insulin secretion is amplified by so called incretin 
effect. Incretins are a group of gastrointestinal hormones including the glucagon-like 
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In type 2 
diabetic patients the incretin effect has been reported to be reduced (72). In particular, the 
impaired postprandial GLP-1 response has been reported in T2DM individuals, with 
obesity (72, 73), insulin resistance (74) and glucose intolerance (73) as a determinant of 
decreased GLP-1 secretion. 
2.2.1.2 Insulin sensitivity 
There are three major insulin-sensitive tissues: skeletal muscle (accounting for ~60-70% of 
the whole body glucose uptake), liver (~30%) and adipose tissue (~10%) (75). Insulin 
resistance is defined as an impaired ability of insulin to stimulate glucose uptake in insulin 
sensitive tissues. Obesity is the most common underlying cause of insulin resistance. Excess 
adipose tissue leads to an increased release of FFAs which directly affect insulin signalling, 
reduce glucose uptake, increase triglyceride synthesis and induce gluconeogenesis in the 
liver (76). Insulin resistance is a key pathophysiologic event  in the development of T2DM. 
The pancreas compensates for impaired insulin action through increased insulin secretion, 
but after the period of compensated insulin resistance, T2DM usually develops due to 
impaired insulin secretion. Insulin acts through binding to insulin receptor, which results in 
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receptor autophosphorylation, activation of receptor tyrosine kinases, and followed by 
phosphorylation of insulin receptor substrates (IRS). Phosphorylation of IRS leads to 
activation of PI3K. Following steps include activation of Akt and PKC kinases which 
mediate translocation of GLUT4 to the plasma membrane (77). 
2.2.1.2.1 Adipose tissue insulin sensitivity 
Adipose tissue affects whole body glucose metabolism through regulation of FFAs levels, 
secreting adipokines and lipogenesis (78). Adipose tissue from lean individuals 
preferentially secretes anti-inflammatory adipokines (e.g., adiponectin, TGFβ, IL-10, IL-4, 
IL-13, IL-1Ra and apelin) while adipose tissue from obese subjects mainly releases 
proinflammatory cytokines (e.g., TNFα, IL-6, leptin, visfatin, resistin, angiotensin II and 
plasminogen activator inhibitor type 1) (79). It was demonstrated that the levels of FFAs 
and TNFα are significantly elevated, contributing to insulin resistance by affecting the 
insulin signalling cascade (80). On the other hand, adiponectin, a major adipocyte-secreted 
protein, is downregulated in obesity (81). Adiponectin increases insulin sensitivity by 
stimulating fatty acid oxidation and inhibition of hepatic gluconeogenesis (82). 
2.2.2 Factors predisposing to type 2 diabetes 
Similar to obesity, T2DM is caused by the combination of environmental signals and 
genetic factors to a varying extent. T2DM has been shown to aggregate in families. The risk 
of developing T2DM is approximately 40% in offspring of one diabetic parent and 
approximately 70% if both parents have the disease (83). However, family members share 
not only genes but also environment, such as dietary habits, socio-economical background 
and many other lifestyle aspects. Major risk factors for diabetes include obesity, with 
special emphasis on visceral obesity, aging, physical inactivity, drinking, smoking, sleep 
deprivation, low-socioeconomic status and ethnicity and impaired intrauterine 
environment (45, 84). Many of the T2DM associated risk variants regulate insulin secretion 
(71), suggesting that the deciding inherited component is related to insulin secretion, 
whereas the environmental component may relate to the energy excess, obesity and 
following insulin resistance (85). 
2.2.2.1 Environmental factors 
The epidemic of T2DM observed over the recent years indicates the importance of 
environmental factors in T2DM onset. Overweight and obesity are the most important 
determinant of T2DM (83). Even mild obesity increases the risk of T2DM; for example, it 
was observed that women with a BMI between 23 and 25 kg/m2  have 3-times higher risk of 
developing diabetes compared with women with a BMI below 23 kg/m2, whereas for 
women with BMI 35 the risk is 20 times higher (86). A number of lifestyle aspects are 
known to be important to the development of T2DM, including sedentary behaviour, diet 
choices and smoking (87). Lack of physical activity was shown to increase the T2DM risk, 
independent of obesity (88). Additionally, it was demonstrated that, independent of BMI, 
quality of diet plays an important role in the development of disease. Particularly, a low-
fibre diet with a high glycemic load increases risk of T2DM (89), and higher intake of 
saturated fat and trans-fat (90) may modify insulin resistance and the risk of T2DM. Active 
smoking has been associated with increased risk of T2DM, which might be linked with 
antiestrogenic effect of smoking and abdominal obesity observed more often in smokers 
(91). The evidence from meta-analyses suggests an approximately 30% reduced risk of 
T2DM in moderate alcohol consumers (6-48 g/day) compared with heavier consumers or 
abstainers (92). Moderate alcohol consumption increases HDL cholesterol levels (93) and is 
associated with lower fasting insulin and triglyceride concentrations and enhanced insulin 
sensitivity (94).  Sleep deficiency is associated with T2DM potentially by altering eating 
habits, inflammation, impairing glucose tolerance and insulin sensitivity (95). 
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2.2.2.2 Genetics of type 2 diabetes 
Multiple lines of evidence support the view that T2DM is inherited. First, the genetic 
differences in T2DM disease predisposition has been observed in different ethnic groups 
(96). The T2DM prevalence varies from very low levels in tribes of Mapuche Indian, to very 
high levels in the Nauru and the Pima Indians (6, 97). Observation of full-blooded 
Nauruans revealed that the prevalence of T2DM is higher than those with admixture (98), 
and the prevalence of T2DM in the Pima Indians is inversely related to the extent of 
interbreeding with the European Americans (98, 99). Familial aggregation provides another 
evidence for a genetic contribution to disease. The heritability of T2DM in twin and 
adoption studies ranges from 45% to 85% (100-102). Only three genes, PPARG, KCNJ11 and 
TCF7L2 were identified as established genes associated with common forms of T2DM by 
linkage and candidate-gene studies (103). Advances using genome wide association 
analyses allowed the discovery of multiple risk variants. Importantly, the genes identified 
by linkage and candidate-gene approaches, PPARG, KCNJ11 and TCF7L2, were confirmed 
as T2DM risk loci. The risk variant in the TCF7L2 gene locus is the most influential common 
variant with allelic odds ratio of ~1.5 (104). TCF7L2 is a key component of canonical Wnt 
signalling pathway. Carriers of the TCF7L2 risk variant show impaired insulin secretion 
(105) and increased hepatic glucose production (106). The current count of firmly 
established T2DM risk loci is now 90 (45). However, these associated loci explain only 5–
10% of the trait variance (107).  As discussed previously, several options have been debated 
to be a source of missing heritability, such as structural variations (55), gene-gene (58), 
gene-environment interactions (54), and epigenetic modifications (59) to name a few. 
2.3 WEIGHT LOSS  
Both obesity and T2DM are intimately linked, since obesity is an important contributor to 
the pathogenesis of insulin resistance (85). Treatment of obesity influences insulin 
resistance. Recommended treatments for both T2DM and obesity include dietary and 
behavioural modifications, bariatric surgery, or a combination of the above mentioned. All 
those approaches have their own advantages and shortcomings. Most of the programs 
modifying lifestyle change result in 5–10% weight loss and are effective for 6–12 months, 
after which weight regain is usually observed. Lifestyle changes and reduction of body 
weight improves glycemic control, mortality and morbidity. Weight loss induced by calorie 
restriction, exercise, life style changes or surgical interventions results in reduction of 
insulin resistance and glycemic control in patients with T2DM or a delay in the 
development of T2DM in pre-diabetic individuals (26). Successful lifestyle interventions 
include self-monitoring of weight, dietary intake, and physical activity (108). The usage of 
medications to assist in weight loss is limited by side effects. Most of the anti-obesity drugs 
that were approved and marketed over the years have been withdrawn due to severe 
adverse effects (109). The weight loss achieved with the medications is 2% to 8% higher 
compared to a placebo effect (108). To determine the role of alternative splicing in obesity 
and weight loss, we conducted experiments using tissue samples from before and after a 
very low calorie diet and the bariatric surgery. 
2.3.1 Very low calorie diet 
Weight reduction is a keystone of the modern treatment of overweight and obese 
individuals. Calorie-restriction strategies are the most common dietary approach, where 
calories are restricted every day, to a minimum of 40-50% of normal caloric intake (110). 
One of the calorie-restriction strategies for the treatment of obesity is very low calorie diet 
(VLCD) characterized by limiting energy intake to 800 kcal (3.35 MJ) per day.  Weight loss 
on VLCD is on average approximately 1.5 to 2.5 kg/week with a total loss after 12 to 16 
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weeks of approximately 20 kg (111).  The VLCD provides at least 50g of proteins and amino 
acids, essential fatty acids, and daily requirements of trace elements, vitamins and minerals 
(112). After weight reduction, the energy intake can be increased gradually to maintain a 
balance between calories consumed and calories expended. However, long-term weight 
loss maintenance is poor, with 50% of weight being regained within one year (113). 
2.3.2 Roux-en-Y gastric bypass 
Whereas many dietary interventions can lead to the short-term weight loss, most of them 
fail to result in a long-lasting effect. Bariatric surgery results in substantial and durable 
long-term weight loss and may be curative for T2DM. In recent years bariatric surgery has 
been used as a treatment for severe obesity and more recently as a treatment for T2DM 
(114). The Roux-en-Y gastric bypass (RYGB) leads to glycemia normalization in 84-98% 
patients (115). The gastric bypass surgery has become the most commonly used bariatric 
surgery procedure. The RYGB is a type of weight loss surgery that involves the division of 
the stomach into a small gastric pouch and gastric remnant. The gastric pouch is connected 
to the jejunum, the middle section of the small intestine, bypassing the remainder of the 
stomach and the duodenum (Figure 2). The surgery leads to the creation of two limbs, the 
alimentary and the biliopancreatic limb. The first one is the branch of the "Y" through 
which food passes, whereas the other transports secretions from the pancreas, liver, and 
gastric remnant (114). Interestingly, many T2DM patients who undergo RYGB are relieved 
of their hypoglycemic medications in a matter of days, before any significant weight loss 
takes place (115). The mechanisms of gastric bypass induced weight loss depends on many 
factors including gut hormones (increased GLP-1 and PYY and reduced ghrelin), changes 
in energy expenditure, reduction in food intake, changes in food choices (possibly due to 
changes in taste and food perception), changes to gut microbial and bile salts metabolism 
(26, 116, 117).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Roux-en-Y gastric bypass. Reproduced from Bariatric surgery: a best practice article, 
Neff KJ, le Roux CW, J Clin Pathol. 2013 Feb;66(2):90-8 with permission from BMJ Publishing 
Group Ltd. 
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2.4 ALTERNATIVE SPLICING 
Despite the fact that obesity and T2DM are highly interrelated, both diseases can develop 
independently. There is no doubt that both T2DM and obesity are inherited, yet the overlap 
between loci for these traits is rather poor. Of 90 loci associated with T2DM only 5 loci is 
shared with 39 BMI associated loci (45). The mechanisms by which these diseases may or 
may not manifest together remain poorly understood.  One possible explanation is that 
alternative splicing provides a mechanism for the modulation of risk factors associated with 
obesity and T2DM.  
Genetic information flows from DNA to RNA and then to protein. DNA is transcribed in 
the nucleus into pre-mRNA which  must undergo mRNA processing before being exported 
to the cytoplasm. mRNA processing is a complex cascade consisting of splicing (both 
constitutive and alternative), 5’capping, 3’polyadenylation and nuclear export of mature 
mRNA (118). Mature mRNA is then exported to the cytoplasm for translation into protein 
(Figure 3). 
 
Figure 3. Flow of genetic information. 
 
Alternative splicing was discovered in 1977 by two independent researchers, Richard J. 
Roberts and Phillip A. Sharp, who were jointly awarded the Nobel Prize in Physiology or 
Medicine in 1993 for discovery of  “split genes” (119, 120). Recent estimates suggest that 
almost all human multi-exon genes are subject to alternative splicing (10, 11). The transcript 
abundance is regulated by promoter activity whereas the structure of transcripts –  
resulting in protein localization, activity, binding properties and post-translational 
modifications – is regulated by alternative splicing (13). Alternative splicing has 
drawn more attention after the completion of a map of the human genome in 2001, which 
revealed that our genome previously estimated to contain ~120,000 genes (121), contains 
only 20,000-25,000 protein-encoding genes (122). Alternative splicing of pre-mRNA is a 
common mechanism responsible for the generation of transcript and protein diversity. 
There are seven main types of common alternative splicing events: 1) alternative 
transcription start site, 2) alternative poly-A site, 3) exon skipping, 4) intron retention, 5) 
mutually exclusive exon usage, 6) 3’ splice site selection and 7) 5’ splice site selection 
(Figure 4). One gene can be subject to the combination of different types of alternative 
splicing, and the splicing events may differ between tissue types. Depending on the tissue 
type or the environment, one gene can be transcribed into suitable transcripts (12).  
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Figure 4. Common types of alternative splicing. Exons are represented by boxes, introns by 
solid lines indicate introns and splicing options are shown with dashed lines. Transcription start 
sites are indicated with arrows and polyadenylation sites with (A). 
2.4.1 Regulation of alternative splicing 
Regulation of alternative splicing is multi-factorial and depends on the regulatory sites on 
the pre-mRNA and corresponding protein activators. Additionally, alternative splicing is 
regulated by physiological signals, allowing an organism to adapt to the alterations in the 
environment (Figure 5). 
Figure 5. Different levels of regulation of alternative splicing 
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2.4.1.1 Basal splicing machinery 
Splicing takes place in the nucleus and is catalyzed by a large ribonukleoprotein complex 
called spliceome. Spliceome includes five small uridine rich ribonucleoproteins (snRNAs: 
U1, U2, U4, U5, and U6) and at least 170 distinct proteins (123).  
Alternative splicing is regulated by the cis-acting regulatory sequence elements 
and trans-acting RNA-binding proteins. There are four different types of cis-acting 
elements, which are short sequences within the pre-mRNA: 1) exonic splicing enhancers, 2) 
exonic splicing silencers, 3) intronic splicing enhancers and 4) intronic splicing silencers. 
One cis-acting element can serve both as an enhancer or silencer, depending on the trans-
acting factor binding to it. The function of cis-acting elements is weak which is 
compensated by the clustering of many cis-acting elements. Trans-acting proteins include 
serine/arginine-rich proteins (SR proteins) and heterogeneous nuclear ribonucleoproteins 
(hnRNPs). hnRNP proteins usually bind to splicing silencers preventing the binding of 
snRNPs or SR proteins whereas SR proteins usually bind to splicing enhancers (124).  
Regulation of alternative splicing depends on the abundance of trans-acting proteins, 
both hnRNPs and SR-proteins. The level of expression of trans-acting proteins may differ 
between different tissue types resulting in tissue-specific alternative splicing (125). 
Interestingly, the trans-acting factors can also be alternatively spliced and are involved in 
auto-regulation (126, 127). 
2.4.1.2 Phosphorylation-mediated regulation 
The components of the pre-mRNA splicing machinery are subject to phosphorylation and 
dephosphorylation during the splicing process. Both, phosphorylation and 
dephosphorylation, of SR proteins was shown to modulate splicing (128, 129). 
2.4.1.3 Coupling between transcription and splicing 
Regulation of alternative splicing involves also the coupling between transcriptions and 
splicing. Two models were proposed to explain the role of RNA polymerase II (RNA pol II) 
in alternative splicing: recruitment model and kinetic model. In the recruitment model, the 
binding of SR proteins to RNA pol II results in alternative exon skipping (130). The kinetic 
model proposes that alternative exon skipping is a result of the fast elongation rate, which 
can be influenced by the level of RNA pol II phosphorylation and chromatin structure (60). 
2.4.1.4 Histone modifications and chromatin structure in splicing regulation  
Recently, histone modifications such as methylation, acetylation and phosphorylation were 
reported to play a role in the regulation of alternative splicing (62). Additionally, siRNAs 
have been suggested to be involved in modulation of chromatin structure near alternatively 
spliced gene regions (131).  
2.4.2 Alternative splicing in diseases 
Misregulation of alternative splicing plays a significant role in diseases. Aberrant splicing 
can result from point mutations (SNPs), which have been compiled in the databases (132, 
133). It is estimated that as much as one third of all disease-causing mutations modify 
mRNA splicing (134-136). Aberrant splicing leading to disease can be a consequence of 
polymorphism situated within cis-acting elements or misregulation of the splicing 
machinery by environmental stimuli. A large number of reviews describe the roles of cis-
acting mutations in diseases (137, 138), and some of the mutations were linked to obesity 
and T2DM (Table 1). 
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Table 1. Splicing mutations in obesity and T2DM related phenotypes 
 
Phenotype Gene Mutation Manifestation Ref. 
   Clinical Molecular  
Obesity 
 
PHF6 
NM_001015877.1:c.769A>G 
(rs104894919) 
Mild Börjeson-
Forssman-
Lehmann 
syndrome 
exon 3 
skipping, 
impaired 
protein function 
(139) 
GNB3 
NM_002075.3:c.825C>T 
(rs5443) 
Obesity 
in frame 
deletion, 
truncated 
protein 
(140) 
LEPR 
NM_002303.5:c.2597+1G>A 
(CS982253) 
Early-onset 
morbid obesity 
and pituitary 
dysfunction 
exon 18 
skipping, 
truncated 
protein  
(141) 
LRRFIP1 
NM_001137552.1:c.2069G>C 
(rs11680012) 
Abdominal 
adiposity and 
inflammation 
altered exonic 
splicing 
(142) 
ALMS1 NM_015120.4 :c.11873-3T>G 
Alström 
syndrome 
exon 19 
skipping, 
truncated 
protein 
(143) 
Hyper- 
glycemia 
 
INSR 
NM_000208.2:c.1124-2A>G 
(rs587776819) 
Rabson-
Mendenhall 
syndrome 
exon 5 
skipping, 
premature stop 
codon 
(144) 
GCK 
NM_000162.3:c.580-1G>A 
(CS052048) 
MODY, 
gestational 
diabetes 
in frame 
insertion  
(145) 
HNF-1α 
NM_000545.5:c.1623+1G>A 
(CS016023); 
NM_000545.5:C.956-2A>G 
(CS016022); 
NM_000545.5:c.1502-6G>A 
(CS024751) 
MODY 
exon 8 
skipping; 
exon 5 
skipping; 
exon 7 
skipping; 
truncated 
proteins 
(146) 
G6PC2 
NM_021176.2:c.441-26T>C 
(rs560887); 
NM_021176.2:c.441-25G>A 
(rs2232321) 
Elevated fasting 
plasma glucose 
exon 4 inclusion (147) 
GIPR 
NM_000164.2:c.1152+820T>A 
(rs10423928) 
Impaired insulin 
secretion, 
increased risk 
of T2DM 
reduced 
expression of 
fully active 
receptor 
(148) 
CDKAL1 
NM_017774.3:c.371+11426A>C 
(rs10946398) 
Increased risk 
of T2DM 
reduced 
expression  of 
CDKAL1  
(149) 
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2.4.2.1 Regulation of alternative splicing by body weight and diet 
There are few reports linking alternative splicing to obesity and weight loss. Reduced 
expression of several trans-acting factors in liver and skeletal muscle of obese humans was 
observed, suggesting common dysregulation of splicing in obesity.  Importantly, reduced 
expression of RNA processing genes was also demonstrated in a mouse model of diet-
induced obesity. Downregulation of trans-acting factor, TRA2B, led to a higher level of 
lipogenesis due to altered splicing of the LPIN1 and increase of β isoform (22).  Alternative 
splicing of troponin T (TNNT3) is another example demonstrating the relation between 
body weight and alternative splicing. The ability to regulate skeletal muscle composition 
was partially impaired in obese rats due to aberrant splicing of Tnnt3 in rats (150).  
Additionally, aberrant splicing of mTOR, caused by a knock-out of trans-acting factor 
Sam68, led to the generation of the truncated variant of mTORi5 and lean phenotype in 
mice (151). 
Gastric bypass surgery induced weight loss, but not diet, resulted in aberrant splicing of 
Nnat in mice, indicating different mechanisms of weight loss (152). Finally, high-fat diet 
was shown to affect splicing of tau in the brain of female mice (153). Mice fed a cafeteria 
diet demonstrated modified splicing pattern of insulin-degrading enzyme (Ide) in mouse 
liver (154). 
2.4.3 Alternative splicing of TCF7L2 
Common intronic variation within the gene encoding transcription factor 7-like 2 
(TCF7L2) has been strongly associated with T2DM in all ethnic groups (104). Moreover, the 
GWAS analyses indicate the strongest association between T2DM and the TCF7L2 locus 
(155), yet the molecular mechanisms on how variations in the gene lead to increased risk of 
developing T2DM have remained elusive. Alternative splicing of TCF7L2 has been 
suggested to explain the association between TCF7L2 SNPs and impaired TCF7L2 function 
in T2DM. Several research groups reported tissue-dependent splicing of TCF7L2 in human 
tissues including pancreas, pancreatic islets, colon, liver, monocytes, primary lymphocytes, 
skeletal muscle, subcutaneous and visceral adipose tissue, peripheral blood mononuclear 
cells and lymphoblastoid cell lines, but no association between splicing and genetic variants 
has been determined (156-160).  
Human TCF7L2 is composed of 18 exons and is characterized by a complex splicing 
pattern in different tissues. The 3’ terminus of TCF7L2 gene is subject to extensive splicing, 
while the 5’ terminus is the stable region amongst different transcript variants. Alternative 
splicing of exons 12, 13, 13a and 13b results in proteins with short, medium or long reading 
frames (161). Exons 13, 13a and 13b are spliced in a mutually exclusive and specific manner, 
with exon 13 expressed in adipose tissue, both subcutaneous and visceral, exon 13a in liver 
tissue and exon 13b in pancreas (156, 160, 162, 163) (Figure 6). 
Figure 6. Alternative splicing of TCF7L2 gene. Constitutive exons of TCF7L2 are represented as 
black boxes and alternative exons as coloured boxes with yellow boxes indicating mutually 
exclusive exons.  
 
Inclusion of full exon 14 introduces binding sites for C-terminal protein binding protein 
(CTBP), an inhibitor of Wnt/β-catenin signalling pathway (164-166), while only variants 
containing exon 13 encode a CRARF domain, required for potent activation of the Wnt 
signalling cascade (165, 167). Hence, changes in TCF7L2 splicing could alter diabetes risk 
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through alterations in Wnt pathway. It has been reported that protein isoforms generated 
by alternative splicing of TCF7L2 exhibit a different ability to activate Wnt signalling 
pathway. A reduced activation of Wnt/β-catenin target gene promoters was demonstrated 
for short TCF7L2 transcript variant (exons 12, 13 and 13a deficient) (168). Furthermore, 
overexpression of the short mRNA transcript variant induced impaired insulin secretion 
and apoptosis in human islets while the overexpression of the full length TCF7L2 mRNA 
transcript variant (including exons 12, 13 and 13a) exhibited the protective effect on β-cell 
function and survival (169). Moreover, it is well known that inhibition of Wnt/β-catenin 
signalling induces adipogenesis (170-172).  
2.4.4 Alternative splicing of INSR 
Human insulin receptor gene consists of 22 exons, with alternatively spliced exon 11 
(Figure 7). 
Figure 7. Alternative splicing of INSR gene. Constitutive exons are represented as black boxes 
and alternatively spliced exon is shown in red.  
 
The insulin receptor (INSR) exists in two protein isoforms arising from inclusion (INSR-
A) or skipping of exon 11 (INSR-B). Expression of the INSR protein isoforms varies between 
tissues and depends on tissue developmental stage. While the INSR-A protein isoform is 
predominantly expressed in fetal cells and is involved in fetal development, the INSR-B 
protein isoform is expressed in mature differentiated cells. These two protein isoforms 
exhibit different functions. INSR-A was shown to promote growth due to its ability to bind 
IGF-II and proinsulin in addition to insulin, while INSR-B is responsible for regulation of 
glucose homeostasis and is a highly specific receptor for insulin (173). The alternative 
splicing of INSR gene in T2DM has been studied mainly in skeletal muscle. In most, but not 
in all of the studies high expression of INSR-B transcript in skeletal muscle was associated 
with T2DM and insulin resistance (173). The increased expression of INSR-B was reported 
in adipocytes isolated from 10 T2DM patients compared with 11 normoglycemic 
individuals (17). Regulation of adipose tissue splicing of INSR in the context of obesity and 
weight loss has not been studied.  
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3 Aims of the Study 
The main objective of this study was to investigate the role of the regulation of alternative 
splicing in obesity and T2DM (Studies I-III). Additionally we have published the review 
(IV) covering recent advances in understanding the role of alternative splicing in obesity 
and insulin resistance. 
 
 
The specific aims were as follows: 
 
1. To determine the splicing profile of the T2DM candidate gene, TCF7L2, in the 
subcutaneous and visceral adipose tissue and in the liver and its correlation with 
clinical parameters. To investigate whether the alternative splicing of TCF7L2, is 
regulated by weight loss (Study I). 
 
2. To determine the splicing profile of INSR in the subcutaneous and visceral adipose 
tissue and its association with clinical parameters. To determine whether the 
alternative splicing of INSR is regulated by weight loss (Study II). 
 
3. To investigate alternative splicing of genes in obesity loci, and to identify differences 
in the splicing profile between lean and obese individuals (Study III). 
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4 General Experimental Procedures 
4.1 STUDY SUBJECTS 
4.1.1 Kuopio Obesity Surgery study (Studies I, II & III) 
All subjects undergoing Roux en-Y gastric bypass surgery at the Kuopio University 
Hospital were recruited into the ongoing Kuopio Obesity Surgery (KOBS) study (>90% 
participated) investigating metabolic consequences of bariatric surgery (174, 175). Study I 
included a total of 95 severely obese individuals, while Study II & III included 110 severely 
obese participants who underwent laparoscopic gastric bypass surgery with alimentary 
limb of 100 cm in Kuopio University Hospital. There were three criteria for surgery (1) 
BMI≥40 kg/m2 or BMI≥ 35 kg/m2 with significant comorbidity (T2DM), (2) failure of dietary 
and drug treatments and (3) no other contraindication for operation. Each participant had a 
one-day visit in hospital for screening eligibility to bariatric surgery, which included an 
interview on disease history, current medication status and an assessment of glucose 
tolerance and cardiovascular risk factors. Fasting blood samples were drawn after 12 hours 
of fasting. Subcutaneous and visceral adipose tissue biopsies were collected during the 
operation. Subcutaneous fat biopsies were taken a year after surgery. Clinical parameters 
were assessed prior to the surgery (at baseline) and at 1-year postsurgery (follow-up) (Table 
2). In Study I, 95 liver biopsies were analyzed at baseline and 11 liver biopsies at follow-up 
(Table 1 in (163)).  
The study was approved by the Ethics Committee of the University of Eastern Finland 
and Kuopio University Hospital, and it was in accordance with the Helsinki Declaration. 
 
Table 2.  Characteristics of the KOBS study subjects. 
 
 Study I  Study II & III 
 
Baseline 
n=54 
Follow-up 
n=46 
p value  
Baseline 
n=108 
Follow-up 
n=81 
 
p value 
Sex male/female 15/39 14/32   34/74 26/55  
Age years 45.4±8.0 46.6±8.1   47.1±9.1 47.6±9.0  
BMI kg/m2 45.0±5.9 34.6±6.1 6×10-21  45.0±6.3 34.6±5.8 2×10-37 
Fasting glucose mmol/l 6.7±1.8 5.5±0.8 3×10-6  6.7±1.7 5.6±0.9 2×10-8 
Fasting insulin pmol/l 123.0±68.4 64.8±70.8 1×10-5  135.7±135.5 71.4±67.4 3×10-10 
 
4.1.2 Metabolic Syndrome in Men study (Studies I, II & III) 
A total of 49 men were included to a Study I & II and 46 participants were included in 
Study III from the population-based Metabolic Syndrome in Men (METSIM) study (176). 
The male subjects, aged from 45 to 70 years, were randomly selected from the population 
register of the town of Kuopio. Each participant had a one-day visit to the Clinical Research 
Unit at the University of Eastern Finland, which included an interview on disease history, 
current medication status and an assessment of glucose tolerance and cardiovascular risk 
factors. Fasting blood samples were drawn after 12 hours of fasting followed by an oral 
glucose tolerance test (OGTT). The characteristics of the subjects are given in Table 3.  
The study was approved by the Ethics Committee of the University of Eastern Finland and 
Kuopio University Hospital, and it was in accordance with the Helsinki Declaration.  
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Table 3.  Characteristics of the METSIM study subjects. 
 
 
4.1.3 Functional Genomics of Type 2 Diabetes study (Study I) 
Functional Genomics of Type 2 Diabetes (EUGENE2) study included healthy non-diabetic 
individuals but who were the offspring of patients with T2DM. One of the parents had to 
have T2DM while the other a normal glucose tolerance or a lack of history of T2DM in first-
degree relatives. The probands were randomly selected among T2DM subjects living in the 
town of Kuopio. T2DM among the probands was defined according to the WHO criteria. 
All participants underwent physical examination, routine blood tests, OGTT, an IVGTT on 
a separate occasion, followed by a hyperinsulinemic-euglycemic clamp (177). A total of 113 
individuals were included to the Study I (Table 4). The study was approved by the Ethics 
Committee of the University of Eastern Finland and Kuopio University Hospital, and it was 
in accordance with the Helsinki Declaration. 
 
Table 4.  Characteristics of the EUGENE2 study subjects. 
 
 Study I 
 
NGT 
n=113 
Sex male/female 49/64  
Age years 40.4± 5.9  
BMI kg/m2 26.8 ± 5.1  
Fasting glucose mmol/l 5.3 ± 0.5  
Fasting insulin pmol/l 63.6 ± 33.6  
 
4.1.4 Very Low Calorie Diet study (Studies II & III) 
A study group of 35 obese, non-diabetic subjects with a BMI between 30 and 45 kg/m2 were 
recruited to the very low calorie study (VLCD). Participants followed very low calorie diet 
(VLCD) of 2,510 kJ/day (600 kcal/day) for 7 weeks (Nutrilett; Leiras Co., Finland). They 
supplemented their diet with low calorie vegetables as desired. The weight loss period was 
followed by a 24-week weight-maintenance period (WM). Clinical parameters and 
subcutaneous tissue biopsies were collected at all visits (baseline, 7 weeks and 24 weeks) 
(178). A total of 32 participants were included to the Study II & III (Table 5).  
The study was approved by the Ethics Committee of the University of Eastern Finland and 
Kuopio University Hospital, and it was in accordance with the Helsinki Declaration. 
 
 
 
 
 
Study I, II  Study III 
 
NGT 
n= 28 
T2DM 
n= 21 
 
p value 
 NGT 
n= 26 
T2DM 
n= 20 
 
p value 
Sex male/female 28/0 21/0   26/0 20/0  
Age years 56.7±5.3 56.3±5.5 0.803  56.5 ± 5.5 56.7 ± 5.3 0.902 
BMI kg/m2 23.2±1.4 26.0±3.9 0.004  23.1 ± 1.4 26.1 ± 3.9 0.003 
Fasting glucose mmol/l 5.5±0.3 7.0±1.1 3×10-6  5.5 ± 0.3 7.1 ± 1.0 1 × 10 -6 
Fasting insulin pmol/l 27.6±8.4 65.4±47.4 0.002  27.6 ± 8.8 62.9 ± 47.3 0.004 
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Table 5.  Characteristics of the VLCD study subjects. 
 
 
4.2 MATERIALS AND METHODS 
4.2.1 Analytical methods used in human studies 
Plasma glucose, insulin, and serum lipids and lipoproteins (total cholesterol, HDL 
cholesterol, and triglycerides) and FFAs were measured from fasting venous blood 
samples. Plasma glucose was measured by enzymatic hexokinase photometric assay 
(Konelab Systems Reagents; Thermo Fischer Scientific, Vantaa, Finland). Plasma insulin 
was determined by immunoassay (ADVIA Centaur Insulin IRI, number 02230141; Siemens 
Medical Solutions Diagnostics, Tarrytown, NY). An oral glucose tolerance test (OGTT) was 
carried after a 12-h fasting period. Serum FFAs were assayed with an enzymatic 
colorimetric method (Wako NEFA C test kit; Wako Chemicals, Neuss, Germany). Glucose, 
insulin, and FFA levels were determined at 0, 30, and 120 min in an OGTT. Intravenous 
glucose tolerance test (IVGTT) and hyperinsulinemic-euglycemic clamp were performed 
after a 12-h fast. In order to determine the first-phase insulin release, an IVGTT was 
performed. A bolus of glucose (300 mg/kg in a 50% solution) was given within 30 s into the 
antecubital vein. Samples for the measurement of blood glucose and plasma insulin were 
drawn at −5, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, and 60 min. Whole-body insulin sensitivity was 
assessed with the hyperinsulinemic-euglycemic clamp technique (insulin infusion rate of 40 
mU ×min−1 × m−2 body surface area), as described (179). Blood glucose was clamped at 5.0 
mmol/L for the next 120 min by infusion of 20% glucose at various rates according to blood 
glucose measurements made every 5 min. The mean amount of glucose infused during the 
last hour was used to calculate the rates of whole-body glucose uptake. Adipose tissue 
insulin sensitivity was estimated from the levels of serum FFAs during the clamp (163). 
4.2.2 Adipose tissue biopsies 
Adipose tissue samples of the KOBS study were taken as open biopsies from subcutaneous 
and visceral adipose tissue during Roux-en-Y gastric bypass surgery (at baseline) and at 1-
year postsurgery (follow-up) open biopsies from subcutaneous adipose tissue were taken 
under local anaesthesia. Adipose tissue samples of the METSIM and EUGENE2 studies 
were taken by a needle biopsy from subcutaneous adipose tissue under local anaesthesia. 
Adipose tissue samples of the VLCD study were taken at all visits (baseline, 7 weeks and 24 
weeks) as an open biopsy from subcutaneous adipose tissue under local anaesthesia. 
Collected adipose tissue samples were stored in -80°C until used for RNA extraction. 
4.2.3 Cell-culture experiments 
Human Simpson-Golabi-Behmel syndrome (SGBS) preadipocytes, which are characterized 
by a high capacity for adipogenic differentiation (180), were morphologically differentiated 
into mature adipocytes. Preadipocytes were cultured in Dulbecco’s modified Eagle’s 
 
Study II & III 
 
Baseline 
n=32 
7 weeks VLCD 
n=32 
24 weeks WM 
n=32 
p value 
(VLCD) 
p value 
(WM) 
Sex male/female 9/23 9/23 9/23   
Age years 48.8±8.7 49.0±8.8 49.5±8.8   
BMI kg/m2 34.7±2.7 29.9±2.4 30.3±2.8 3×10-24 2×10-16 
Fasting glucose mmol/l 6.1±0.8 5.6±0.6 5.7±0.6 1×10-4 6×10-5 
Fasting insulin pmol/l 82.8±46.2 40.8±19.2 51.0±27.0 3×10-6 4×10-6 
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medium/F12 Nut mix supplemented with 33 μM biotin, 17 μM pantothenate, 1% 
penicillin/streptomycin, and 10% FBS until reaching confluence. To induce differentiation, 
preadipocytes at day 0 were washed three times with PBS and cultured in serum-free 3FC 
medium (Dulbecco’s modified Eagle’s medium/F12 nut mix, 33 μM biotin, 17 μM 
pantothenate, 1% penicillin/streptomycin, 0.01 mg/mL transferrin, 20 nmol/L insulin, 0.1 
μM hydrocortisone, and 0.2 nmol/L T3) with 25 nmol/L dexamethasone, 0.5 μM 
isobutylmethylxanthine, and 2 μM rosiglitazone. At day 4 of postdifferentiation, the 
medium was changed to 3FC medium with 25 nmol/L dexamethasone and 0.5 μM 
isobutylmethylxanthine. At day 7 of postdifferentiation, the medium was changed to 3FC 
medium, and after that, the medium was replenished twice a week with 3FC medium (163). 
4.2.4 RNA isolation and reverse transcription 
Total RNA was extracted and purified using the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany). Total RNA was converted to cDNA with random primers using a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s protocol. (163).  
4.2.5 Analysis of alternative splicing and sequencing 
Relative ratio of splice variants of analyzed genes were analyzed with the PCR-capillary 
electrophoresis method. Our method, based on a single PCR, was optimized to give reliable 
information on the isoform distribution and on changes of the isoform distribution due to 
alternative splicing. The cDNA equivalent of 2 ng total RNA was amplified by PCR in a 
thermocycler (ABI PRISM 2720; Applied Biosystems).  PCR reaction was performed using 
DyNAzyme II Hot Start DNA Polymerase (Finnzymes, Espoo, Finland) and a suitable 
primer pair flanking an alternatively spliced region resulting in PCR products that vary in 
size depending on splicing. The reverse primers were fluorescein (FAM)-labelled. The 
primers used in this study are shown in Table 6. Amplicon reactions were run on the ABI 
3100 the ABI 3100 DNA Genetic Analyzer (Applied Biosystems) using POP6 polymer 
(Applied Biosystems). The results were analyzed using Peak Scanner Software v1.0 
(Applied Biosystems). Peak areas were used to calculate the relative quantities of PCR 
products. PCR products were initially gel-purified and sequenced in order to determine 
exon incorporation and ensure the specificity of amplification using BigDye Terminator 
v1.1 (Applied Biosystems) (163). 
 
Table 6. Primer pairs used for detection of splice variants 
 
PCR primer  Primer forward (5’ – 3’) Primer reverse (5’ – 3’) Study 
TCF7L2 exon 3 - 5 ATCCCCGACCTGACGAGCCC  GAGGTGGGTTTCCCGGCGTG I 
TCF7L2 exon 11-14 CAGCCGGGAGAGACCAATG TGGGTCTGCTCAGTCTGTGACT I 
INSR  ACCAGAGTGAGTATGAGGATTCGG TCCGGACTCGTGGGCACGCTGGTC II 
RPGRIP1L  GCACCAAGACCTAAACCAAGACAACG TGCCAAGCTTTGTTCTGCAAGCTG III 
MSH5 TGGACCCACATGCCCCCACA TGATGGGTTTTCCACTGCGGATCA III 
CKAP5 CCTGAACCCAAGATCCGGGCTG CCTCCCGGGCAAGGCTCTCT III 
SMARCD1 CTGCTGTCCACTGCCAGCCA CGGCACACAGCCTCCTGAGC III 
SPNS1 GTAGTGCGGGAGCCGCCAAG CCCAGGACTCCGGTCAGGCA III 
SH3YL1 TACACCGCGGCCTGCTCAAG TCCCCAGGCTGCTGTCCTTCA III 
ACP1 TGTCGATCACCCATTGCAGAAGC TGCAGCACCTGACACACTGC III 
BAG6 GTTCCGAGTGCTCCCACTGGC CGCCCTGCAGTGTCCCAGAG III 
TRA2B GTCATGAGCGACAGCGGCGA ATGGCTGTGGCTGTGCCGTC III 
LAT TGGTGCCAACAGTGTGGCGAG AGACGCTTCTGCGCTCTCCC III 
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4.2.6 Total gene expression analysis 
Quantitative RT-PCRs were conducted in a 7500 Real-Time PCR System (Applied 
Biosystems) using cDNA as template (equivalent of 3 ng total RNA) and gene-specific 
primers that placed on constitutive exons flanking a region which was not subject to 
alternative splicing. PCR products were detected using SYBR Green (KAPA SYBR FAST 
qPCR Kit; Kapa Biosystems, Woburn, MA). Gene expression was normalized 
to RPLP0 (ribosomal protein, large, P0). Primers for SYBR Green PCR were designed using 
Primer3 v. 0.4.0. (163). Primer information is presented in Table 7. Additionally, expression 
of HNRNPA1, SF3A1, SFRS7 and TRA2B was determined by the TaqMan Gene Expression 
Assays (Applied Biosystems) (Hs01656228_s1, Hs01066327_m1 and Hs01032694_g1 
respectively) according to the protocol and their expression was normalized to RPLP0 
expression (Hs99999902_m1). 
 
Table 7. Primer pairs used for detection of total gene expression 
 
PCR primer  Primer forward (5’ – 3’) Primer reverse (5’ – 3’) Study 
TCF7L2 total  TGTCTCTAACAAAGTGCCAGTG GGTAAGTGTGGAGGTGGGTTT I 
INSR total ACCCCAATGGCAACATCACCCAC TGGACAGGAGCAGCATTCGCC II 
RPLP0 GGCGACCTGGAAGTCCAACT CCATCAGCACCACAGCCTTC I, II 
4.2.7 Genotyping 
In study I, genomic DNA was isolated from whole blood, and used as a template for 
genotyping of TCF7L2 rs7903146 with the TaqMan Allelic Discrimination Assay (Applied 
Biosystems). 
4.2.8 Statistical analysis 
Data analyses were conducted with the SPSS/Win programs (SPSS Inc., Chicago, IL). Data 
from the same individual at the different time points (KOBS and VLCD studies) were 
compared with paired t tests, whereas data between study groups with unpaired two-
tailed t tests. Correlations were assessed with nonparametric Spearman correlations. 
A P value <0.05 was considered statistically significant. Logarithmic transformation was 
used to obtain normal distribution whenever needed (indicated in the tables and figures). 
Descriptive statistics are presented as mean ± SDs (163). 
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5 Results  
5.1 ADIPOSE TISSUE TCF7L2 SPLICING IS REGULATED BY WEIGHT 
LOSS AND IS ASSOCIATED WITH GLUCOSE AND FATTY ACID 
METABOLISM 
In Study I (also reviewed in R IV) we investigated alternative splicing of TCF7L2 in the 
context of obesity surgery induced weight loss and the association of TCF7L2 splicing with 
the levels of plasma glucose and serum free fatty acids (FFAs) in three independent study 
cohorts (n=216 combined: KOBS n=54, EUGENE2 n=113 and METSIM n=49). Furthermore, 
we investigated the possible association between TCF7L2 splicing and rs7903146 
polymorphism associated with T2DM.  
We have demonstrated reduced expression of the short mRNA transcript variant 
(lacking exons 12, 13, 13a and 13b) after weight loss both in subcutaneous fat (n=46) and 
also in the liver (n=11) (Figure 8). 
Figure 8. Change in expression level of TCF7L2 splice variants during the year after gastric 
bypass surgery in subcutaneous fat and liver. *p<0.05; **p< 0.01; ***p< 0.001, paired t- 
test. ND- not detected (163). 
  
In addition, observed expression of the short mRNA transcript variant was higher 
among individuals with T2DM than in those with normal glucose tolerance in both KOBS 
and METSIM studies (Figure 9A).  The short mRNA transcript variant positively correlated 
with the level of fasting glucose in individuals of all three studies (Figure 9B). Finally, short 
mRNA transcript variant exhibited positive correlation with FFAs in both subcutaneous 
and visceral adipose tissue depots (Figure 9C). We observed the association between short 
mRNA transcript variant and high levels of serum FFAs during hyperinsulinemia 
suggesting impaired insulin action in adipose tissue (Figure 9D). We did not observe any 
association with insulin secretion (Figure 9E) or insulin-stimulated whole body glucose 
uptake (Figure 9F) in the EUGENE2 study. We did not find an association between splicing 
and common risk SNP, which may be due to a relatively small sample size. Finally, we 
observed no change in total TCF7L2 expression suggesting that effect on splicing is 
independent of transcription regulation. 
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Figure 9. A. Prevalence of the short TCF7L2 transcript variant in subcutaneous fat in individuals 
with and without T2DM in the KOBS and METSIM studies.  Mean±SD shown. *p<0.05; 
**p<0.01. B. Scatter plot demonstrating correlation between the short TCF7L2 transcript 
variant expression and fasting plasma glucose in the KOBS, EUGENE2 and METSIM studies in 
subcutaneous fat (KOBS, r=0.335, p=0,016; METSIM r=0.382, p=0.011; EUGENE2, r=0.218, 
p=0.026). C. Scatter plot demonstrating correlation between the expression of the short 
TCF7L2 transcript variant in subcutaneous fat (SF, r=0.350, p=0.014) and visceral fat (VF, 
r=0.581, p=1.8×10-5) and fasting plasma glucose and serum free fatty acids (FFAs) in the 
KOBS study. D. Insulin action in adipose tissue measured as serum FFA levels at 120min after 
an oral glucose load (OGTT) (n=216, all studies combined) or as serum FFA levels at the end of 
40mU euglycemic clamp (n=113, EUGENE2 study) in individuals with low or high prevalence of 
the TCF7L2 short transcript variant (divided by the median value). Mean ± SD shown. *p<0.05; 
***p< 0.001 E. Insulin secretion measured during intravenous glucose tolerance test (IVGTT) 
and F. insulin sensitivity measured as a whole-body glucose uptake during the 
hyperinsulinemic-euglycemic clamp in the EUGENE2 study in individuals with low or high 
prevalence of the TCF7L2 short transcript variant (divided by the median value) (163). 
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In addition, we observed an increased proportion of short TCF7L2 transcript variant, 
with reduced capacity to activate Wnt/β-catenin signalling, during adipocyte 
differentiation. Importantly, inhibition of Wnt/β-catenin signalling is well known to 
activate adipogenesis (170-172).  
To conclude, we demonstrated that the short TCF7L2 mRNA transcript variant, 
characterized by lack of exons 12,13,13a and 13b, in subcutaneous adipose tissue is 
regulated by weight loss and associated with hyperglycemia and impaired insulin action in 
adipose tissue.  
5.2 ADIPOSE TISSUE INSR SPLICING IN HUMANS IS ASSOCIATED 
WITH FASTING INSULIN LEVEL AND IS REGULATED BY WEIGHT LOSS  
In Study II we investigated alternative splicing of INSR in response to weight loss, induced 
either by obesity surgery or dietary intervention. Based on our earlier findings, that the 
expression of several RNA processing genes is reduced in obesity, we hypothesized that 
INSR splicing in adipose tissue is modified by weight loss due to changes in expression of 
trans-acting factors regulating alternative splicing. We investigated the association of INSR 
splicing with the expression of trans-acting factors and metabolic traits in three 
independent studies (n=189 combined: KOBS n=108, VLCD n=32 and METSIM n=49).  
In Study II we reported for the first time that alternative splicing of INSR in adipose 
tissue is associated with BMI (Figure 10A). Furthermore, we demonstrated that alternative 
splicing of INSR in adipose tissue is regulated by weight loss induced both by gastric 
bypass surgery (Figure 10B) and dietary intervention (Figure 10C). The proportion of INSR-
B mRNA variant was decreased in adipose tissue of T2DM subjects in METSIM study and 
similar trend was observed in KOBS study (Figure 10D). We observed strong negative 
correlation between insulin levels and INSR-B splice variant in subcutaneous adipose tissue 
in all three studies (Figure 10E).  
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Figure 10. The relative proportion of INSR-B in subcutaneous fat (SF) (A) in the METSIM, VLCD 
and KOBS studies at baseline and in response to (B) obesity surgery in the KOBS (white bar, 
baseline; black bar, 1 year postsurgery) and (C) to a 7 week very low calorie diet (VLCD) 
followed by a 24 week weight-maintenance (WM) period (white bar, baseline; black bar, 7 
weeks VLCD; grey bar,  24 weeks WM). (D) Relative proportion of the INSR-B variant in 
individuals with and without type 2 diabetes in the METSIM and KOBS studies. White bars, non-
diabetic subjects; black bars, subjects with type 2 diabetes (T2DM) (E) Scatter plot 
demonstrating the correlation of INSR-B with logarithmically transformed fasting insulin levels 
in pooled samples from the KOBS, VLCD and METSIM studies (r=-0.649, p=3×10-22). White 
triangles,  non-diabetic subjects (ND, n=123, r=-0.676, p=4×10-16); grey circles, subjects with 
type 2 diabetes (T2DM n=66, r=-0.601, 3×10-7). Mean±SD shown. ***p<0.001 (A,B) vs. 
baseline of same study (C) and vs. non-diabetic subjects of same study (181). 
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We did not detect any change in total expression of INSR gene, indicating that effect on 
splicing was independent on transcription. Finally, INSR splicing was correlated with 
expression of HNRNPA1, a known regulator of INSR splicing (182). 
 
To conclude, we demonstrated that INSR splicing is strongly associated with fasting 
insulin levels and is regulated by weight loss, possibly through the alterations in the trans-
acting factors expression. 
5.3 REGULATION OF ALTERNATIVE SPLICING IN HUMAN OBESITY LOCI 
Recent GWAS analyses increased the number of loci associated with obesity risk. Yet, the 
mechanisms of action by which these loci increase susceptibility to obesity remain unclear. 
Most of the functional polymorphisms are non-coding, i.e., they are situated in intronic or 
intergenic regions. However, non-coding polymorphisms can influence either the 
regulation of transcription or act at the level of regulation of mRNA processing leading to 
change in protein expression or protein sequence. Reduced expression of several trans-
acting factors in the liver and muscle of obese individuals suggests an important role of 
alternative splicing in human obesity (22). The role of genetic regulation of splicing in 
obesity was suggested based on enrichment of rare SNPs  in intronic splicing regulatory 
regions of obese subjects (20). 
We postulate that alternative splicing of genes in obesity loci may contribute to obesity. 
To this aim we selected 136 genes in 11 obesity loci based on analysis of approximately 
40000 individuals (38, 183) and we screened 25 genes, coding for different protein isoforms 
(Figure 11).  
Figure 11. Analysis pipeline to identify alternatively spliced variants in the obesity loci.  
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 We detected alternative splicing of 10 genes in obesity loci, three of which (TRA2B, 
BAG6, MSH5) were differently spliced between lean normoglycemic and overweight T2DM 
subjects (Figure 12). 
 
 
Figure 12. The relative proportion of (a) TRA2B var2 (b) BAG6 varX7 and (c) MSH5 var1 in the 
subcutaneous fat of the lean normoglycaemic individuals (NGT) and overweight type 2 diabetic 
individuals in the METSIM study. Mean±SD shown. Comparison made using t- test, **p< 0.01, 
***p<0.001. 
 
 In addition, we detected different splicing pattern of BAG6 varX7 and TRA2B var2 
transcript variants between subcutaneous and visceral fat depots (Figure 13).  
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Figure 13. Difference in expression level of TRA2B, BAG6 and MSH5 splice variants between 
subcutaneous fat and visceral fat in the KOBS study. Mean±SD shown. Comparison made using 
paired t- test, *p< 0.05, ***p<0.001. 
 
Moreover, our analysis revealed that MSH5 splicing was regulated by weight loss in two 
independent intervention (KOBS and VLCD) studies (Figure 14). 
 
Figure 14. Change in expression level of MSH5 var1 during the year after gastric bypass surgery 
(white bar, KOBS study)  and during a 7 week very low calorie diet (VLCD) followed by a 24 
week weight-maintenance (WM) period (black bar, VLCD study) in subcutaneous fat. 
Comparison made using paired t- test, **p< 0.01.  
 
Finally the forward stepwise multivariate analysis indicated that BMI was an 
independent determinant of TRA2B, BAG6 and MSH5 splicing profile in pooled data from 
the METSIM and KOBS studies. Age was the only determinant of TRA2B splicing in 
visceral fat.  
 
To conclude, our study identifies alternative splicing in obesity loci. These findings 
imply that the obesity-associated SNPs might act through regulation of splicing which in 
turn might underlie the pathogenesis of obesity in individuals carrying the risk SNPs.  
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6 Discussion 
6.1 REGULATION OF TCF7L2 BY OBESITY AND WEIGHT LOSS (STUDY I) 
TCF7L2 gene, coding for transcription factor 7-like 2, is the most important candidate 
gene for T2DM, confirmed in many populations. Since its discovery in 2006 (184), several 
research groups have reported associations of TCF7L2 rs7903146 polymorphism with 
impaired insulin secretion, linking the polymorphism function with the pancreatic β-cell 
(105, 185). TCF7L2 is known to play a role at the last stage of the canonical Wnt/β-catenin 
signalling pathway, regulating the expression of a set of target genes. Despite the obvious 
association between T2DM risk and TCF7L2, the mechanism through which TCF7L2 has 
effects on T2DM remains very unclear (186). 
In the Study I we demonstrated, that weight loss regulates alternative splicing of 
candidate gene, TCF7L2, in subcutaneous fat and liver (Figure 8). Subcutaneous adipose 
tissue splicing of TCF7L2 is associated with obesity, levels of fasting plasma glucose and 
FFAs. Importantly, we observed an association between TCF7L2 splicing and fasting FFAs 
in both subcutaneous and visceral fat. Additionally, we observed the association between 
TCF7L2 splicing pattern and insulin action in adipose tissue (Figure 9D). The observed 
correlations are highly statistically significant but they are relatively weak which results 
from both, relatively small sample size and human genetic diversity. We did not observe 
any change in total gene expression following weight reduction. Our results are in 
agreement with the earlier reports with respect to distribution of transcript variants in 
adipose tissue and liver (159, 160). We did not find the association between rs7903146 
genotype of TCF7L2 and transcript variants, but we cannot exclude the possibility of an 
association with our relatively small sample size for genetic study.  
TCF7L2 splicing can affect cell metabolism through modifying Wnt/β-catenin signalling, 
as it was shown that transcript variant lacking exons 12,13, 13a and 13b has impaired ability 
to induce Wnt/β-catenin signalling (168, 169). Exclusion of exons 13 and 13a results in lack 
of CRARF and CRALF motifs (165, 167) required for the activation of Wnt/β-catenin target 
promoters (168). The exact pathways responsible for the change in TCF7L2 splicing after 
obesity surgery should be investigated in experimental studies. Aberrant splicing of 
TCF7L2 in obesity could be related to insulin resistance. Insulin has been shown to regulate 
trans-acting factors (22, 187) and their reduced expression was demonstrated in obesity (22).   
To summarize, in Study I we demonstrated that the short TCF7L2 transcript variant 
characterized by lack of exons 12, 13, 13a and 13b in subcutaneous adipose tissue is 
regulated by weight loss and is associated with high levels of plasma glucose and impaired 
insulin action in adipose tissue. Findings of the Study I could be explained by impaired 
ability of the short TCF7L2 transcript variant to activate Wnt/β-catenin signalling in adipose 
tissue. These results suggest that the regulation of TCF7L2 splicing in adipose tissue may 
contribute to increased diabetes risk (Figure 15).  
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Figure 15. Alternative splicing of exons 12-13b of TCF7L2 can lead to a short less functional 
isoform. This isoform associates with adipose tissue insulin resistance and with elevated levels 
of serum free fatty acids and plasma glucose. This suggested model is based on our study 
published in Diabetes (2012, vol. 61, (11), pages 2807-2813) (188). 
 
6.2 REGULATION OF INSR BY OBESITY AND WEIGHT LOSS (STUDY II) 
The insulin receptor, coded by the INSR gene, exists in two isoforms, which are result of 
alternative splicing of 36 nucleotide-long exon 11. Both INSR variants were shown to be 
expressed in developmentally and tissue-specific manner. The INSR-A (lacking exon 11) 
variant is predominantly expressed in fetal cells and plays a role in fetal development, 
whilst the INSR-B (including exon 11) variant is expressed in differentiated cells. INSR-A 
binds insulin, IGF-II and proinsulin, while INSR-B binds highly specifically insulin. As a 
result INSR-A predominantly promotes growth and INSR-B regulates glucose homeostasis 
(173). Almost thirty years after discovery of the two insulin receptor splice variants, the role 
of INSR isoforms in T2DM remains unclear since data reported by different groups are 
contradictory (173).  
In Study II we demonstrated that weight loss regulates alternative splicing of INSR in 
adipose tissue, regardless of the weight reduction approach. The INSR splicing pattern 
depends on BMI, with reduced expression of INSR-B transcript variant in obese subjects. 
The proportion of INSR-B mRNA variant, the more active isoform in insulin signalling 
(189), was increased in response to weight loss induced by both obesity surgery and VLCD 
(Figure 10A-C). We observed higher expression of INSR-B was higher in normoglycaemic 
individuals than T2DM subjects in METSIM study. But the strongest detected correlation in 
all examined studies was with insulin levels (Figure 10E). Our analysis revealed that fasting 
insulin is the main determinant of the INSR splicing in subcutaneous adipose tissue, which 
is in line with a previous study in monkeys, suggesting a link between hyperinsulinemia 
and INSR splicing (190, 191). Importantly, insulin levels were strongly negatively correlated 
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with INSR-B proportion both in subcutaneous and visceral fat indicating common insulin 
action regulation. 
Aberrant splicing of INSR in obesity could be related to insulin levels, as it is known that 
insulin regulates trans-acting factors activity (22, 187, 192) and their reduced expression was 
demonstrated in obesity (22).  Moreover, we observed a correlation between splicing 
pattern of INSR and expression of HNRNPA1, previously reported to inhibit exon 11 
inclusion in HepG2 and HEK293 cells (182). We acknowledge that other regulators of INSR 
splicing exist (182), and they may also be modified by weight loss. The main limitation of 
this study is that INSR protein isoforms created by alternative splicing could not be 
detected because the difference between the protein isoforms is only 1 kDa. 
To summarize, in Study II we demonstrated that the adipose tissue INSR-B transcript 
variant, characterized by inclusion of exon 11, is regulated by weight loss and is strongly 
associated with fasting insulin. Findings of the Study II could be explained by changes in 
splicing factor activity through phosphorylation (192). We propose that changes in adipose 
tissue INSR splicing in response to obesity could be mediated by changes in expression of 
splicing factors (Figure 16). 
 
Figure 16. Proposed mechanisms for changes in alternative splicing of INSR gene in obesity. 
Obesity induced changes in transcription of trans-acting factors, e.g. HNRNPA1, result in altered 
splicing pattern of INSR gene favouring INSR-A variant involved in cell growth. 
 
6.3 IDENTIFICATION OF ALTERNATIVE SPLICING OF GENES IN 
OBESITY LOCI (STUDY III) 
During past years GWAS analyses revealed several loci associated with obesity, yet the 
causal gene and mechanism in most cases remains elusive. The attempts to resolve the 
functional significance of these loci are challenging since majority of them are located in 
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intronic or intergenic regions. One possibility is that SNPs in the obesity loci could affect 
splicing of genes. 
In Study III we applied bioinformatics approach and conducted PCR capillary 
electrophoresis to investigate the importance of alternative splicing of genes in obesity loci.  
We demonstrated the evidence that 10 out of 136 genes residing in obesity loci are 
alternatively spliced in human adipose tissue. We identified altered splicing pattern 
between T2DM and non-diabetic individuals in 3 out of 11 genes (MSH5, BAG6 and 
TRA2B). Furthermore, we detected different splicing patterns of BAG6 and TRA2B genes 
between subcutaneous and visceral fat depots. Moreover, we have identified lower 
expression of MSH5var1 in overweight T2DM subjects and increase of this variant 
following weight loss, regardless of the weight reduction approach used.  
We demonstrated that BMI was an independent determinant of TRA2B splicing in 
subcutaneous fat. TRA2B splicing has a known autoregulatory function, with low 
expression levels of TRA2B inducing the generation of variant missing exon 2 (193). 
Additionally, expression of TRA2B was demonstrated to be reduced in skeletal muscle and 
liver of obese individuals (22). Thus, our observations support the role of TRA2B in human 
obesity (22).  
We also detected lower proportion of BAG6 varX7 in visceral compared to subcutaneous 
adipose tissue. BAG6 is involved in apoptosis, gene regulation and is a regulator of protein 
synthesis and degradation (194).  A mechanism on how the aberrant splicing 
of BAG6 contributes to obesity remains to be determined. 
MSH5 protein plays a role in development and meiosis (195) and in non-meiotic tissues in 
DNA damage repair (196). The function of MSH5 in adipose tissue metabolism remains 
unknown. The MSH5 gene is subject to alternative splicing and exists in three protein 
isoforms. Functional properties of these protein isoforms are unknown. Polymorphisms 
within MSH5 gene have been associated with many human diseases such as cancer, 
immune diseases and reproductive disorders (197). Additionally, we investigated the effect 
of inflammatory factors on the MSH5 splicing pattern in SGBS cell strain, but we observed, 
if any, the opposite trend than expected suggesting that reduced inflammation associated 
with weight reduction is not responsible for observed changes in three independent 
studies. Statistical analyses revealed that BMI is a main determinant of TRA2B, BAG6 and 
MSH5 splicing in subcutaneous fat. 
To summarize, in Study III we identified alternative splicing in obesity loci. We 
identified altered splicing pattern between obese T2DM and lean non-diabetic individuals 
suggesting the importance of alternative splicing in pathogenesis of obesity and/or T2DM. 
We showed the fat depot dependent regulation of alternative splicing of BAG6 and TRA2B. 
The significance of these variants needs to be further investigated. Finally, we have 
observed reduced expression of MSH5var1 in obese T2DM subjects and weight loss 
induced increase of this variant in two independent weight reduction studies. The function 
of alternative splicing of MSH5 in adipose tissue and its possible implications to obesity 
requires further examination. 
6.4 EVALUATION OF THE METHODS 
6.4.1 Study subjects 
This work was based on the results from four study cohorts (KOBS, METSIM, EUGENE2 
and VLCD) all of them well characterized and the subjects were phenotyped in detail. 
Subjects for weight intervention studies were carefully selected; subjects were obese 
(VLCD) and severely obese (KOBS). All subjects of this study had a one day visit to the 
hospital or Clinical Research Unit at the University of Eastern Finland, including an 
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interview on their history of previous diseases, current drug treatments and cardiovascular 
risk factors. All study subjects were of Finnish descent. 
6.4.2 Alternative splicing analysis 
We implemented PCR capillary electrophoresis for sensitive detection of subtle changes in 
the splicing pattern. The benefit of this method is that many transcript variants can be 
analyzed at the same time using single PCR. Internal size standard allows for 
determination of the analyzed fragment size. These factors make PCR capillary 
electrophoresis a great choice of method for candidate gene study. Relative abundance of 
each transcript variant was determined by dividing the area under the peak by the total of 
all peak areas. The advantage of this method is that there is no need to use endogenous 
control.  Additionally, the change in relative ratio between existing splice variants is not 
affected by a small fluctuations in the total transcript level. The method provides 
exceptional sensitivity and transcript size accuracy which in turn allows the identification 
of the transcript variants and the quantification of the ratio of all transcript variants 
examined. The PCR capillary electrophoresis method do not allow for absolute 
quantification of the variants.  There are however few limitations of the method to be 
mentioned. The PCR capillary electrophoresis method is suitable for analysis of single gene, 
not a high-throughput analysis which is the main limitation of the methods. Additionally, 
primers spanning the regions around alternatively spliced regions allow for detection of 
cassette exons but PCR based method is not suitable for detection of alternative 
transcription start site and alternative poly (A) site events. These limitations can be 
overcome by implementation of the high-throughput transcriptome assessment 
technologies. Development of the high-throughput techniques, such as RNA-sequencing 
(RNA-seq), enables the investigation of alternative splicing patterns on a genome wide 
scale. RNA-seq provides millions of short sequence reads from one- or both-ends of the 
sequenced fragment, which results in large scale and high sensitivity transcript data. 
However, analysis of RNA-seq data, especially in the presence of genes with large numbers 
of alternative transcripts has turned this into a challenging task due to the complexity of the 
information. 
6.4.3 Total gene expression 
Quantitative RT-PCR method was implemented in order to determine the total gene 
expression level.  The method is sensitive and allows quantification of total gene 
expression. The data obtained with qPCR are relative and require normalization using the 
reference gene, which is the main limitation of the method. 
6.5 CONCLUDING REMARKS (REVIEW IV) AND FUTURE PLANS 
The overall function of alternative splicing is to increase transcriptome variability and 
coding capacity of the genome. Aberrant splicing leading to disease can result from point 
mutation within cis-acting elements (137, 138) or misregulation of the splicing machinery by 
environmental stimuli. There are numerous obesity related genes regulated by alternative 
splicing. The finding, that expression of several RNA processing genes is reduced in liver 
and skeletal muscle of obese humans, suggests that aberrant splicing in obesity might be a 
common phenomenon. It is important to notice that although trans-acting factors and 
alternative splicing events can be modulated in obesity they can also contribute to the 
metabolic status, as demonstrated for trans-acting factor, TRA2B, and its target-exon 6 of 
LPIN1 gene (22). The aberrant splicing in obesity might be related to insulin levels since 
activity of trans-acting factors, SR (192) and HNRNP proteins (198), were shown to be 
regulated by insulin (22, 187, 192).  Therefore, both, insulin resistance observed in obese 
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individuals and improved insulin signalling accompanying weight loss may influence 
splicing (Figure 17).  
 
Figure 17. Proposed mechanisms for changes in alternative splicing in obesity. Changes in 
phosphorylation (P in the figure) and transcription of SR proteins may alter splicing leading to 
protein isoforms with different function. These effects may interact with single nucleotide 
polymorphisms (SNPs) in critical intron-exon boundaries. Dashed arrows refer to our own 
recently published data in Cell Metabolism (2011, vol. 14, (2), pages 208-2018)(188). 
 
There is undisputed evidence that both obesity and T2DM are hereditary conditions. In 
spite of the fact that GWAS analyses have identified several genetic risk variants for obesity 
and T2DM, the SNPs identified so far only explain a fraction of the obesity (50) and T2DM 
(107) risk. The missing heritability may result from rare variants (55), copy number variants 
(55), interaction effects between different SNPs (199), epigenetic modifications (59-63), 
gene-gene (G×G)(57, 58) and gene environment (G×E) (54) interactions that are not detected 
in GWAS.  It is important to point out that regulation of alternative splicing might be 
affected at several levels, as shown in Figure 5, such as transcription, epigenetic 
modifications or environmental stimuli, which provides a possible link between missing 
heritability and alternative splicing. Studies described here, providing the evidence that 
alternative splicing of candidate genes is affected by weight loss, indicate an important role 
of alternative splicing in mediating the gene-environment interaction. 
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Study III, describing a systematic evaluation for alternative splicing in GWAS loci, 
revealed the need of utilizing the whole transcriptome RNA sequencing to detect all 
splicing events in a large sample size with a longitudinal setting allowing for investigation 
of intra-individual regulation. Our future plans include a genome wide analysis of 
alternative splicing in adipose tissue and its relation to risk gene variants in the METSIM 
and KOBS studies. Additionally, we aim to determine the association between alternative 
splicing and weight loss in KOBS study. Genotyping and RNA-seq analysis on samples 
extracted from the KOBS and METSIM studies will be performed in collaboration with 
Prof. Päivi Pajukanta at the University of California, Los Angeles (UCLA). This systematic 
study will provide a better understanding of the relationship between alternative splicing, 
genotypes and obesity and/or T2DM on genome wide scale. 
 
There is certainly much more to discover about alternative splicing function in metabolic 
pathways and pathophysiology of metabolic diseases. The number of genes affected as well 
as trans-acting factors affecting alternative splicing in metabolic disorders is very likely to 
expand. Future studies, implementing genome wide analyses, should help in identifying 
the role of alternative splicing in metabolism, but also provide opportunities for new 
diagnostic and possible personalized therapeutic approaches. 
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7 Summary 
The main findings of Studies I-III were as follows. 
 
Study I: Alternative splicing of TCF7L2 is regulated by weight loss and is associated with 
high levels of plasma glucose and serum FFAs. These findings could be explained by 
different ability of TCF7L2 splice variants to activate Wnt/β-catenin signalling in adipose 
tissue.  
 
Study II: Alternative splicing of INSR is regulated by weight loss and is strongly associated 
with fasting insulin. These findings could be explained by changes in splicing factor activity  
 
Study III: Genes in obesity loci are regulated by alternative splicing. These findings imply 
that the obesity-associated SNPs might act through regulation of splicing which in turn 
might underlie the pathogenesis of obesity in individuals carrying the risk SNPs. Adipose 
tissue depot dependent splicing of TRA2B and BAG6 and weight loss induced regulation of 
MSH5 were demonstrated. Additionally, BMI was shown to be a main predictor of TRA2B, 
BAG6 and MSH5 splicing. 
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Many human diseases can be caused 
by impairment of alternative splicing 
or its regulation. The main aim of 
the present study was to investigate 
interactions between alternative 
splicing of the genes and obesity. 
This thesis provides new informa-
tion on the role of alternative splic-
ing in pathogenesis of obesity and 
type 2 diabetes. These findings in-
crease our understanding of splicing 
dysregulations and can improve the 
chances for a more targeted treat-
ment and more accurate diagnostics.
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